Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Each year approximately 256,000 children and adults around the world develop a form of
leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship
between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia.
XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one
cysteine in the N-terminal residue. It has been found with significant expression of
receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For
these reasons, XCL1 could be a efficient marker of prognosis in patients with acute
Observational Model: Cohort, Time Perspective: Prospective
Number of patients with poor prognosis and high levels of XCL1
Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
Cesar H Gutierrez Aguirre, MD
Hospital Universitario Dr. Jose E. Gonzalez UANL
Mexico: Ethics Committee
XCL1 in ALL